131 results
Page 3 of 7
6-K
EX-99.1
o5hyva9nru
8 Mar 22
Current report (foreign)
8:49am
6-K
EX-99.1
xv0m1gds8
15 Feb 22
Current report (foreign)
4:27pm
6-K
EX-1.1
a52si y7g
11 Feb 22
Current report (foreign)
5:29pm
424B5
cslptdfz ng
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.1
97e 10sdi0zo
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
EX-99.1
94fxjn2t5gr
17 Sep 21
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to
7:36am
6-K
EX-99.2
sefl69 6se3
2 Sep 21
Notice of Annual General Meeting of Shareholders
7:20am
6-K
EX-99.1
noccnrdhcdjmm2t8jmj
30 Aug 21
Current report (foreign)
7:50am
6-K
jch ufqs5mrb748g0ss
16 Aug 21
Current report (foreign)
7:00am
6-K
EX-99.1
8hhnvkupgd4m49cvh65k
8 Jul 21
VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors
4:05pm
6-K
EX-99.1
r9zdwwtwikz
15 Jun 21
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
7:51am
6-K
EX-99.1
cfpycr5l35zep
4 Jun 21
Current report (foreign)
8:05am
6-K
murmurugg2uo4k7a3cy
11 May 21
Current report (foreign)
7:00am
POS AM
inkk8npoetrj933s
19 Apr 21
Prospectus update (post-effective amendment)
5:17pm
424B8
p3gjrvuhz
19 Apr 21
Prospectus unintentially filed late
5:06pm
6-K
EX-1.1
3jw umdakayo3834p
12 Apr 21
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
9:10am
6-K
EX-4.1
qxkd9 ulshm
12 Apr 21
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
9:10am
424B5
5wj37islh742x
12 Apr 21
Prospectus supplement for primary offering
9:07am